Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

Psoriatic Arthritis

Gottlieb A, Menter A, Mendelsohn A et al.Lancet 2009;373:633–40.

Ustekinumab has previously proven to be effective in the treatment of plaque psoriasis, but determining whether it has any effect in treating psoriatic arthritis (PsA) has proven to be more difficult. In the present article, the authors report the results of a Phase II, double-blind, randomized, placebo-controlled, crossover study of patients with PsA who were treated with ustekinumab.

Interleukin-23 (IL-23) and IL-12 amplify the activities of Th17 and Th1 cells, respectively, and both cytokines have been shown to play an important role in the pathogenesis of plaque-type psoriasis [1, 3,4]. These cytokines may also play a part in the pathogenesis of psoriatic arthritis (PsA) [2,3].

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles